ResearcherNo recent work listed

Sean P. Nassoiy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9786-0669; OpenAlex author ID A5091474442. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper

Papers 2

Evolving management of early stage pancreatic adenocarcinoma in older patients. Co-author DOI 10.1016/j.amjsurg.2022.07.026 ↗
Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma. First author DOI 10.1016/j.sipas.2022.100136 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wade O. Christopher · 2 shared papers, 2022–2023 · strength 0.34
- Paper Evolving management of early stage pancreatic adenocarcinoma in older patients. DOI 10.1016/j.amjsurg.2022.07.026 ↗
- Paper Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma. DOI 10.1016/j.sipas.2022.100136 ↗
Melanie R. Goldfarb · 2 shared papers, 2022–2023 · strength 0.34
- Paper Evolving management of early stage pancreatic adenocarcinoma in older patients. DOI 10.1016/j.amjsurg.2022.07.026 ↗
- Paper Neoadjuvant chemotherapy improves outcomes in resectable pancreatic adenocarcinoma. DOI 10.1016/j.sipas.2022.100136 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.